Dr. Ashkan M. Abbey of Texas Retina Associates discussed the results of the DAVIO 2 trial at the ASRS meeting, focusing on EYP-1901 for wet age-related macular degeneration. Patients received loading doses of Eylea and were then assigned either EYP-1901 or bimonthly Eylea. After 6 months, two-thirds of eyes receiving EYP-1901 did not need extra treatment, and there were no significant differences in visual acuity or central subfield thickness between groups. The study indicates promising results for EYP-1901 as a potential treatment option. Abbey reported consulting for EyePoint Pharmaceuticals and being a member of the company’s clinical trial steering committee.
Source link
Supplemental treatment not needed in two-thirds of eyes that received EYP-1901
